Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/33342

Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs
Trigueros Motos, Laia; Pérez Torras, Sandra; Casado, Javier (Casado Merediz); Molina Arcas, Míriam; Pastor Anglada, Marçal
Universitat de Barcelona
Background: Nucleoside analogs used in the chemotherapy of solid tumors, such as the capecitabine catabolite50-deoxy-5-fluorouridine (50-DFUR) trigger a transcriptomic response that involves the aquaglyceroporin aquaporin 3 along with other p53-dependent genes. Here, we examined whether up-regulation of aquaporin 3 (AQP3) mRNA incancer cells treated with 50-DFUR represents a collateral transcriptomic effect of the drug, or conversely, AQP3participates in the activity of genotoxic agents. Methods: The role of AQP3 in cell volume increase, cytotoxicity and cell cycle arrest was analyzed using loss-of-function approaches. Results: 50-DFUR and gemcitabine, but not cisplatin, stimulated AQP3 expression and cell volume, which was partially and significantly blocked by knockdown of AQP3. Moreover, AQP3 siRNA significantly blocked other effects of nucleoside analogs, including G1/S cell cycle arrest, p21 and FAS up-regulation, and cell growth inhibition. Short incubations with 5-fluorouracil (5-FU) also induced AQP3 expression and increased cell volume, and the inhibition of AQP3 expression significantly blocked growth inhibition triggered by this drug. To further establish whether AQP3 induction is related to cell cycle arrest and apoptosis, cells were exposed to long incubations with escalating doses of 5-FU. AQP3 was highly up-regulated at doses associated with cell cycle arrest, whereas at doses promoting apoptosis induction of AQP3 mRNA expression was reduced. Conclusions: Based on the results, we propose that the aquaglyceroporin AQP3 is required for cytotoxic activity of 5’-DFUR and gemcitabine in the breast cancer cell line MCF7 and the colon adenocarcinoma cell line HT29, and is implicated in cell volume increase and cell cycle arrest.
Farmacogenètica
Medicaments antineoplàstics
Pharmacogenetics
Antineoplastic agents
cc-by (c) Trigueros-Motos et al., 2012
http://creativecommons.org/licenses/by/2.0
Artículo
info:eu-repo/semantics/publishedVersion
BioMed Central Ltd
         

Mostrar el registro completo del ítem

Documentos relacionados

Otros documentos del mismo autor/a

Trigueros Motos, Laia; Pérez Torras, Sandra; Casado, Javier (Casado Merediz); Molina Arcas, Míriam; Pastor Anglada, Marçal
Casado, Javier (Casado Merediz); Fernández López, José Antonio; Esteve, M.; Rafecas Jorba, Immaculada; Argilés Huguet, Josep Ma.; Alemany, Marià, 1946-
Fernández López, José Antonio; Casado, Javier (Casado Merediz); Rafecas, Immaculada; Esteve Ràfols, Montserrat; Argilés Huguet, Josep Ma.; Remesar Betlloch, Xavier; Alemany, Marià, 1946-
Casado, Javier (Casado Merediz); Fernández López, José Antonio; Esteve, M.; Rafecas Jorba, Immaculada; Argilés Huguet, Josep Ma.; Alemany, Marià, 1946-
Bolze, A.; Abhyankar, A.; Grant, A.; Patel, B.; Yadav, R.; Byun, M.; Caillez, D.; Lienhardt, P.Y.; Emile, J.F.; Pastor Anglada, Marçal; Abel, L.; Puel, A.; Govindarajan, R.; de Pontual, L.; Casanova, J.L.